Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IRON Stock Forecast 2025-2026
$93.26
Current Price
$3.52B
Market Cap
Buy 13
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IRON Price Targets
+65.1%
To High Target of $154.00
+22.8%
To Median Target of $114.50
-2.4%
To Low Target of $91.00
IRON Price Momentum
-0.1%
1 Week Change
+11.2%
1 Month Change
+43.9%
1 Year Change
+47.1%
Year-to-Date Change
-4.0%
From 52W High of $97.12
+202.6%
From 52W Low of $30.82
📊 TOP ANALYST CALLS
Did IRON Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Disc Medicine is one of their latest high-conviction picks.
Latest IRON Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, IRON has a bullish consensus with a median price target of $114.50 (ranging from $91.00 to $154.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $93.26, the median forecast implies a 22.8% upside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IRON Analyst Ratings
13
Buy
0
Hold
0
Sell
IRON Price Target Range
Low
$91.00
Average
$114.50
High
$154.00
Current: $93.26
Latest IRON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IRON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | Truist Securities | Danielle Brill | Buy | Maintains | $114.00 |
| Nov 3, 2025 | Stifel | Stephen Willey | Buy | Reinstates | $125.00 |
| Oct 30, 2025 | Morgan Stanley | Sean Laaman | Overweight | Maintains | $115.00 |
| Oct 17, 2025 | Raymond James | Martin Auster | Strong Buy | Maintains | $108.00 |
| Oct 17, 2025 | Wedbush | David Nierengarten | Outperform | Maintains | $110.00 |
| Oct 17, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $153.00 |
| Aug 18, 2025 | Morgan Stanley | Sean Laaman | Overweight | Maintains | $90.00 |
| Jul 21, 2025 | Truist Securities | Danielle Brill | Buy | Initiates | $86.00 |
| Jul 3, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $118.00 |
| Jul 3, 2025 | Morgan Stanley | Sean Laaman | Overweight | Assumes | $85.00 |
| Jun 17, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $118.00 |
| Jun 11, 2025 | Raymond James | Michael Freeman | Strong Buy | Reinstates | $89.00 |
| May 12, 2025 | BMO Capital | Evan Seigerman | Outperform | Maintains | $120.00 |
| Mar 18, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $132.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $85.00 |
| Mar 3, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $75.00 |
| Jan 24, 2025 | Stifel | Benjamin Burnett | Buy | Maintains | $94.00 |
| Jan 22, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $73.00 |
| Jan 21, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $118.00 |
| Dec 10, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $90.00 |
Disc Medicine Inc. (IRON) Competitors
The following stocks are similar to Disc Medicine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IRON
Disc Medicine
mkt cap
3.52B
Disc Medicine Inc. (IRON) Financial Data
Disc Medicine Inc. has a market capitalization of $3.52B with a P/E ratio of 5.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -34.8%.
Valuation Metrics
Market Cap
$3.52B
Enterprise Value
$2.96B
P/E Ratio
5.0x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+17.5%
Current Ratio
23.5x
Debt/Equity
5.4x
ROE
-34.8%
ROA
-22.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Disc Medicine Inc. (IRON) Business Model
About Disc Medicine Inc.
What They Do
Develops therapies for hematologic diseases.
Business Model
The company focuses on creating novel therapeutics that target unmet medical needs in blood diseases, particularly those related to iron overload and hemoglobin disorders. By leveraging its research and clinical expertise, it aims to develop treatments that can enhance iron homeostasis, thereby generating revenue through the commercialization of these innovative therapies.
Additional Information
Disc Medicine Inc. is positioned within the biopharmaceutical sector, specifically in hematology, and is dedicated to improving patient outcomes and advancing treatment options in a critical area of healthcare. Its work has implications for both the healthcare industry and patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
142
CEO
Dr. John D. Quisel Esq., J.D., Ph.D.
Country
United States
IPO Year
2020
Website
www.discmedicine.comDisc Medicine Inc. (IRON) Latest News & Analysis
Latest News
Quick Summary
Disc Medicine, Inc. (NASDAQ:IRON) reported positive initial data from its Phase 2 trial of DISC-0974 for anemia of MF, showing significant reductions in hepcidin and increased iron levels.
Why It Matters
Positive Phase 2 trial results for DISC-0974 could enhance Disc Medicine's market position, attract investment, and boost stock performance as it addresses significant medical needs in hematologic diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A fund sold 583,500 shares for about $30.90 million, reducing its holdings to zero. The position previously represented 3.9% of the fund's AUM.
Why It Matters
The fund's complete divestment from a significant position indicates a shift in strategy, potentially affecting future returns and market sentiment surrounding the asset.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Disc Medicine, Inc. (IRON) will present at the Stifel 2025 Healthcare Conference on November 13, 2025, at 8:40 AM EST, featuring COO Jonathan Yu.
Why It Matters
Disc Medicine's participation in the Stifel Healthcare Conference signals potential insights into its strategy and performance, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript
17 days ago
Quick Summary
Disc Medicine, Inc. (IRON) will present at the Jefferies London Healthcare Conference on November 19, 2025, at 9:00 AM EST, featuring CEO John Quisel.
Why It Matters
Disc Medicine's participation in the Jefferies London Healthcare Conference signals potential investor interest and insights into its strategic direction, impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Disc Medicine, Inc. (NASDAQ:IRON) will participate in fireside chats at three upcoming investor conferences, focusing on treatments for serious hematologic diseases.
Why It Matters
Disc Medicine's participation in investor conferences signals potential opportunities for funding and partnerships, which could impact stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Disc Medicine, Inc. (IRON) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters
The inquiry into Disc Medicine's potential as a top stock pick signals investor interest, indicating possible growth and volatility, which can attract momentum trading strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About IRON Stock
What is Disc Medicine Inc.'s (IRON) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Disc Medicine Inc. (IRON) has a median price target of $114.50. The highest price target is $154.00 and the lowest is $91.00.
Is IRON stock a good investment in 2026?
According to current analyst ratings, IRON has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $93.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IRON stock?
Wall Street analysts predict IRON stock could reach $114.50 in the next 12 months. This represents a 22.8% increase from the current price of $93.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Disc Medicine Inc.'s business model?
The company focuses on creating novel therapeutics that target unmet medical needs in blood diseases, particularly those related to iron overload and hemoglobin disorders. By leveraging its research and clinical expertise, it aims to develop treatments that can enhance iron homeostasis, thereby generating revenue through the commercialization of these innovative therapies.
What is the highest forecasted price for IRON Disc Medicine Inc.?
The highest price target for IRON is $154.00 from at , which represents a 65.1% increase from the current price of $93.26.
What is the lowest forecasted price for IRON Disc Medicine Inc.?
The lowest price target for IRON is $91.00 from at , which represents a -2.4% decrease from the current price of $93.26.
What is the overall IRON consensus from analysts for Disc Medicine Inc.?
The overall analyst consensus for IRON is bullish. Out of 15 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $114.50.
How accurate are IRON stock price projections?
Stock price projections, including those for Disc Medicine Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 9:00 AM UTC